Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | KITE-197 |
Synonyms | |
Therapy Description |
KITE-197 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) for an undisclosed target (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KITE-197 | KITE197|KITE 197 | KITE-197 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) for an undisclosed target (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06079164 | Phase I | KITE-197 Cyclophosphamide + Fludarabine | Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma | Recruiting | USA | CAN | AUS | 0 |